Searched over 200M research papers
10 papers analyzed
These studies suggest that metformin doses ranging from 1700 to 3000 mg/day can lead to weight loss in obese individuals, with higher doses potentially achieving greater reductions, especially in specific populations like women with PCOS.
20 papers analyzed
Metformin, a widely used medication for type 2 diabetes, has also been explored for its potential in promoting weight loss. This article synthesizes findings from various studies to determine the optimal metformin dose for weight loss in different populations.
A study comparing two doses of metformin (1500 mg/day and 2550 mg/day) in obese women with polycystic ovary syndrome (PCOS) found that both doses led to significant weight loss. However, the higher dose (2550 mg/day) resulted in greater weight reduction in the obese subgroup (3.6 kg vs. 1.5 kg). This suggests that higher doses of metformin may be more effective for weight loss in this population.
In a trial comparing metformin (1500 mg/day) with polyethylene glycol loxenatide (PEG-Loxe) in overweight or obese patients with type 2 diabetes, metformin resulted in a weight loss of 2.96 kg over 16 weeks. Although PEG-Loxe showed greater weight loss, metformin still demonstrated significant efficacy.
A systematic review and network meta-analysis assessed the efficacy of metformin for weight loss in overweight and obese individuals. The analysis revealed that metformin significantly decreased body mass index (BMI) and weight, with doses of 1000 mg/day and 3000 mg/day being particularly effective in adults. Another meta-analysis confirmed that metformin leads to modest reductions in BMI, especially in individuals with a baseline BMI >35 kg/m².
Research indicates that metformin may promote weight loss by reducing food intake. A study involving non-insulin-dependent diabetes mellitus (NIDDM) patients found that metformin decreased calorie intake and hunger ratings, with the 1700 mg dose showing the most significant effects. This appetite-suppressing action likely contributes to the weight loss observed with metformin.
In children and adults, metformin has shown consistent, albeit modest, weight loss effects. A systematic review highlighted that metformin treatment for at least six months resulted in greater weight reduction compared to controls, with significant improvements in insulin sensitivity and reduced progression towards type 2 diabetes. Another study in obese insulin-resistant children found that metformin (1000 mg twice daily) led to significant decreases in BMI and body weight over six months.
Optimizing metformin dosing to 2000 mg/day or the maximum tolerated dose can improve glycemic control and promote weight loss in type 2 diabetes patients. A study from the GRADE cohort demonstrated that increasing the metformin dose by at least 1000 mg/day resulted in an average weight loss of 0.91 kg.
Metformin is effective for weight loss in various populations, with higher doses generally leading to greater weight reduction. While the optimal dose may vary depending on individual factors such as baseline BMI and insulin resistance, doses ranging from 1500 mg to 3000 mg per day have shown significant efficacy. Further research is needed to refine dosing strategies and understand the long-term impacts of metformin on weight management.
Most relevant research papers on this topic